MaaT-033 is under clinical development by MaaT Pharma and currently in Phase I for Chemotherapy Effects. According to GlobalData, Phase I drugs for Chemotherapy Effects have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MaaT-033’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MaaT-033 is under development for the treatment of chemotherapy effects in acute myeloid leukemia and myelodysplastic syndrome patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is administered by oral route as a capsule. The drug candidate comprises lyophilized biotherapeutic in a controlled-release capsule containing full-ecosystem microbiota pooled from healthy donors, butycore. The drug candidate is developed based on Microbiome Restoration Bio-therapeutic (MMRB) platform.
MaaT Pharma overview
MaaT Pharma (MaaT) is a biotechnology company that develops novel treatments for Gut Microbiota dysbiosis related diseases. The product portfolio in clinical development including one in Phase II are MaaT013 for the treatment of acute graft-versus-host disease and 1 in Phase Ib MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation and in preclinical development and MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors. It also develops treatment for infectious diseases related to onco-hematology in fragile patients. MaaT is headquartered in Lyon, France.
For a complete picture of MaaT-033’s drug-specific PTSR and LoA scores, buy the report here.